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Abstract
Background: Bacopa monniera has been used as a cure for various ailments that include anxiety, epileptic
disorders, dementia, blood purifier, cough and rheumatism, and some important local uses of the plant are in
dermatitis, anemia, diabetes, promote fertility and prevent miscarriage for many years in Bangladesh. According to
this background, the aim of the study was to evaluate the antidepressant-like effect of the methanolic extract of B.
monniera (MEBM) in different behavioral models such as forced swimming test (FST), measurement of locomotor
activity test (MLAT) and tail suspension test (TST) on mice after two weeks treatment.
Methods: Mice were divided into five groups (n = 5/group): control group (deionized water), standard group where
Imipramine hydrochloride (30 mg/kg) was used as standard drug and three test groups where three doses of the
methanolic extract of B. monniera (MEBM) (50, 100, and 200 mg/kg) was used for two weeks treatment. All the drug
and test samples were administered via gavage through oral route. To assess the antidepressant-like effect of MEBM
forced swimming test (FST), tail suspension test (TST) and measurement of locomotor activity test (MLAT) have
been done in mice.
Results: The results showed that a strong and dose-dependent antidepressant effects in different mice models.
The main findings of the MEBM significantly reduced the duration of immobility times in the forced swimming test
(p < 0.001). Likewise, the extract significantly decreased the immobility time in the tail suspension test (p < 0.001).
Moreover, we employed an additional measurement of locomotor activity test to check the motor stimulating
activity of the MEBM. The extract also significantly increased the locomotion, rearing and defecation effects in
comparison to the control group (p < 0.001).
Conclusion: The present results clearly demonstrate that the methanolic extract of B. monniera possesses
antidepressant-like activity in the animal behavioral models. The current study warrants further investigation into
identification of the active compounds in herbal medicines, in particular extract of B. monniera with antidepressant-
like effects.
Keywords: Bacopa monniera, Imipramine hydrochloride, Antidepressant-like effect, Forced swimming, Tail
suspension
Background
Depression is the second leading psychiatric disorder
where 21 % of the world population suffers from this
disease [1]. The age range is markedly decreasing from
40–50 years age range to 25–35 years age range which
observed worldwide [2]. In last few decades, several
drugs have been discovered to treat depression such as
tricyclic antidepressants, monoamine oxidase inhibitors
[3] and selective serotonin reuptake inhibitors (SSRI).
But unfortunately, all of the drugs have serious side ef-
fects including insomnia, anxiety, weight gain etc. It is
well known that nature is the best and safe source for all
medicine. So it becomes worth to search for a new anti-
depressant drug from natural source with less side ef-
fects (It is assume that a drug from natural source could
have less side effects) and complications [4].
Bacopa monniera (Family: Scrophulariaceae), com-
monly known as Brahmi, is an aquatic herbs distributed
throughout the warmer regions of the world including
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Bangladesh. It grows in wet, damp, marshy areas and
possesses a wide range of medicinal values including
memory enhancement, improvement of cognitive disor-
ders, focusing and alertness as well as reduces anxiety
[5, 6]. In Bangladesh, this plant is extensively used in the
traditional medicine system as potent therapeutic agent
as a neurological tonic to enhance intellectual develop-
ment [7], to treat epilepsy [8], cardiac [9], respiratory
[10] and digestive [11] disorders, toothache and purifies
blood. In some parts of this country Brahmi is used to
treat rheumatism and to prevent miscarriage [12]. Con-
versely, B. monniera is associated with gastrointestinal
side-effects, specifically increased bowel movements, nau-
sea, and abdominal cramping [13]. Toxicology studies of
the extract used in the current study—BacoMind,™—have
not shown gastrointestinal reactions in rats [14] and safety
and tolerability studies of BacoMind™ in human volun-
teers reported only mild gastrointestinal reactions in 3 of
23 participants that subsided instinctively. Possibly the
higher incidence of gastrointestinal reactions in the
current study was due to the older age of participants,
lowering their capacity to tolerate Bacopa [13]. There are
several reports revealing that Brahmi contains flavonoids
[15], alkaloids, glycosides, saponins and sterols [16]. Some
researchers isolated some of these phytochemicals such as
Brahmin, nicotine, herpestine, des-saponin glycosides-
triterpenoid saponins like Bacosides A & B. It has
been found that the phytochemicals like 3-(a-L-arabino-
pyranosyl)-O-b-D-glucopyranoside-10 and 20-dihydroxy-
16-keto-dammar-24-ene (Bacosides A & B) are the major
compounds that may exhibit neuropharmacological
activities by directly acting on the neurotransmeter’s
level [17, 18]. The other chemical constituents re-
ported for this plant includes A1 & A3 [19, 20], her-
saponin [21], betulic acid, monnierin [22], herpestin
and brahmine [23], luteolin-7-glucoside, glucoronyl-7-
apigenin and gluucoronyl-7-luteonin, common phytoster-
oids [7]. Due to the diverse pharmacological actions of
Brahmi, research tried to investigate and validate its eth-
nomedical uses based on the advanced research tech-
niques. They found Brahmi as a potent agent with
antioxidant [24], antiulcerogenic [25], cognitive enhancer
[26], anti-inflammatory, anxiolytic [27], analgesic, antipyr-
etic, and sedative [26] properties. However, the neuro-
pharmacological activity of this plant is not investigated
extensively which influenced us to design our study.
The present study investigated the antidepressant-like
effect of MEBM in different behavioral model of de-
pression in mice.
Methods
Plant material and extraction
The leaves of B. monniera were collected from the vil-
lage Khanpur, Bogra, Bangladesh in June, 2014. The
collected samples were then identified by Sarder Nasir
Uddin, Senior Scientific Officer, Bangladesh National
Herbarium, Dhaka, Bangladesh. A voucher specimen
(DACB: 38106) has been deposited in the Herbarium for
further reference. About 250 g of powdered material
have to be soaked in 800 mL methanol at 25 ± 2 °C for
72 h in a beaker and mixture needs to be stirred every
18 h using a sterile glass rod. Filtrate was obtained 3
times with the help of Whatman No. 1 filter paper and
sterilized cotton filter. The solvent was removed by ro-
tary evaporator and 10.56 g extract (Yield 4.22 %) was
obtained. This crude extract was used for the investiga-
tions of antidepressant-like effect of the methanolic ex-
tract of B. monniera in mice.
Animals
Swiss Albino mice (20–25 g) were collected from the
Animal Research Branch of the International Center for
Diarrheal Disease and Research, Bangladesh (ICDDR, B).
Animals were maintained under standard environmental
conditions (temperature: 25.0 ± 2.0 °C, relative humidity:
55–65 % and 12 h light/ dark cycle). Husk and excreta
were removed from the cages every day. Pellets of mice
foods, provided by ICDDR, B were given to the mice
with fresh water ad libitum during acclimatization
period. The animals were acclimatized to the laboratory
environment for a period of 14 days prior to performing
the experiments into five groups such control, standard
and three tests groups (50, 100 and 200 mg/kg). The ani-
mals were fasted overnight before the experiments. All the
experimental animals were treated following the Ethical
Principles and Guidelines for Scientific Experiments on
Animals (1995) formulated by The Swiss Academy of
Medical Sciences and the Swiss Academy of Sciences. All
experimental rules were approved by the Institutional
Animal Ethical Committee (SUB/IAEC/14.01) of Stamford
University Bangladesh.
Drugs and treatments
The described experiments used chemicals and drugs
such as methanol (Merck, Germany), and Imipramine
hydrochloride (Sandoz, Novartis Bangladesh Ltd). The
Table 1 Effects of methanolic extract of B. monniera (MEBM) in
forced swimming test in body weight (g) gain of mice
Treatment Doses (mg/kg) Day 1 Day 14
Deionized water 0.1 mL/mice 22.20 ± 0.86 28.78 ± 1.07
Imipramine hydrochloride 30 23.60 ± 1.12 27.77 ± 1.51
MEBM 50 24.05 ± 1.01 26.11 ± 0.98
MEBM 100 24.54 ± 1.40 24.66 ± 2.99
MEBM 200 24.08 ± 1.07 25.85 ± 1.65
Values are presented as mean ± SEM (n = 5). MEBM =Methanolic extract of
B. monniera
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standard drug Imipramine hydrochloride (30 mg/kg)
was used in antidepressant activity tests. The sample of
methanolic extract of B. monniera and standard drug
Imipramine hydrochloride were prepared by dissolving
in deionized water at the doses of 50, 100, and 200 mg/
kg for sample extract and 30 mg/kg for standard drug
respectively. The test and standard groups were received
MEBM and drugs orally 30 min before the experiments,
whereas the control group received 0.1 mL/mouse de-
ionized water. All the groups received drugs and samples
via gavage. Before the final experiments, all the groups
of animals treated for two weeks. All the chemicals and
the drugs were analytical graded and highly purified.
Antidepressant activity tests
Forced swimming test (FST)
Forced swimming test or behavioral despair test for
measuring the susceptibility to negative mood of mice’s
threat of drowning, commonly used to measure the ef-
fectiveness of antidepressant agents [28]. For assessing
the antidepressant activity of the FST is widely used for
pharmacological model. This method was adapted on
the observation of animals exposed to a situation of
forced swimming, in which they become passive and
immobile after a period of vigorous activity (struggling),
producing only the movements required to keep their
heads above the water. The FST was performed according
to the method of Porsolt [29, 30] with some modifications.
Mice were divided randomly into control, extract and Im-
ipramine hydrochloride. Each group was contained 5
mice. Test solutions were administered once daily be-
tween 1 and 3 p.m. over a period of 14 d. Mice were
placed in an acrylic cylinder (45 cm height = 20 cm
diameter) filled with water at 25 ± 1 °C to a depth of
17 cm for 15 min (pre-test session) after 14 d treat-
ment. Twenty-four hours after the pre-test session,
the animals were once again exposed to the same
conditions for 5 min (test session). Between the pre-
test session and main session drug solutions were ad-
ministered orally three times as follows: just after the
pre-test session, 5 h before the main test, and 1 h be-
fore the main test. A mouse was judged immobile if
it remained floating in the water, except for small
movements to keep its head above the water. The
FST was performed between 1 and 3 p.m. for 5 min
by observers [31].
Measurement of locomotor activity test (MLAT)
The locomotor activity test needs to be performed ac-
cording to the method of Carlini [32] with minor modi-
fications. This test is designed to measure the mobility
of mice. A group of 25 mice was divided at random into
five groups and orally administered with control, extract
or Imipramine hydrochloride 30 min before the experi-
ment. Mice were placed in an open field apparatus com-
posed of an arena 40 cm in diameter divided into 16
approximately equal areas. For open field observations,
each mouse was individually placed in the center of the
arena 15 h after the last treatment. Hand-operated coun-
ters were employed to score the following behavioral
Table 2 Antidepressant effects of methanolic extract of B.
monniera in forced swimming test
Treatment Doses (mg/kg) Immobility Time (s)
Deionized water 0.1 mL/mice 110.60 ± 3.88
Imipramine hydrochloride 30 20.00 ± 1.58*
MEBM 50 57.60 ± 2.65*
MEBM 100 45.60 ± 2.73*
MEBM 200 31.40 ± 2.42*
Values are presented as mean ± SEM (n = 5). MEBM =Methanolic extract of
B. monniera
*p < 0.001 compared with the control group (Dunnett’s test)
Fig. 1 Graphical representation of antidepressant effect of B. monniera extract on forced swimming test of immobility time in mice
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parameters: locomotion (number of line crossings), rear-
ing frequencies (number of times seen standing on hind
legs), and number of defecations within 5 min. Open
field observations was made between 8 and 10 a.m [31].
Tail suspension test (TST)
For screening antidepressant effect and other class of
psychotropics a simple, rapid and reliable method is
TST. The test is designed to assay mood level by meas-
uring the immobility time which indicate change in
mood. This method was employed on the observation
that a mouse suspended by the tail shows alternate agi-
tation and immobility which is indicative of a state of
depression. TST induced immobility is reduced by a
large no of clinically active and atypical antidepressant
effect [33]. The TST was performed according to the
method [34] with slight modifications. 25 mice were
treated with control, extract or Imipramine hydro-
chloride and were placed in the middle of the stand.
Two stands, each with a clamp located 22 cm from
the floor, were placed at intervals of 23 cm. A mouse
was hung 5 cm from the end of its tail on a stand,
and observed for 6 min. The TST was performed be-
tween 1 and 3 p.m. Immobility time was evaluated by
observers [31].
Statistical analysis
The results are presented as mean ± SEM. The statistical
analysis was performed using one way analysis of variance
(ANOVA) followed by Dunnett’s post hoc test as appro-
priate using SPSS 11.5 software. Differences between
groups were considered significant at a level of p < 0.001.
Results
The methanolic extract of B. monniera showed
antidepressant-like effects in prophetic animal models,
namely forced swimming, measurement of locomotor
activity and tail suspension tests. MEBM (50, 100 and
200 mg/kg body weight) or the synthetic antidepressant
drug, Imipramine hydrochloride (30 mg/kg), was orally
administered to the mice once daily for 14d. There was
no difference in body weight gains after 14d among test
treatment groups (Table 1). The extract (50, 100 and
200 mg/kg body weight) significantly reduced the dur-
ation of immobility time in the forced swimming test
after 14d daily treatment (Table 2 and Fig. 1). Dunnett’s
post hoc analysis demonstrated that the test treatments
significantly decreased the immobility time in comparison
to the control group (p < 0.001). Likewise, the extract re-
duced the duration of immobility time in the tail suspen-
sion test (Table 3 and Fig. 2). Post hoc analysis confirmed
that the extract significantly decreased the immobility
time in comparison to the control group (p < 0.001).
The effectiveness of the decreasing immobility in the
FST was also shown previously with psycho stimulants,
which exert an indiscriminate motor stimulating activity.
For this false positive result, we employed an additional
measurement of locomotor activity test to check the
motor stimulating activity of the MEBM. Administration
of the extract of B. monniera at doses of 50, 100 and
200 mg/kg for 14 days, active doses in the FST, resulted
in no behavioral changes or motor dysfunction in the
measurement of locomotor activity test (Table 4 and
Figs. 3, 4 and 5).
Fig. 2 Graphical representation of antidepressant effect of B. monniera extract on locomotor activity test of locomotion in mice
Table 3 Antidepressant effects of methanolic extract of B.
monniera in tail suspension test
Treatment Doses (mg/kg) Immobility Time(s)
Deionized water 0.1 mL/mice 107.40 ± 2.65
Imipramine hydrochloride 30 16.00 ± 2.28*
MEBM 50 50.80 ± 2.35*
MEBM 100 44.40 ± 2.46*
MEBM 200 32.00 ± 1.87*
Values are presented as mean ± SEM (n = 5). MEBM =Methanolic extract of
B. monniera
*p < 0.001 compared with the control group (Dunnett’s test)
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As shown in Fig. 3, MEBM (50 and 200 mg/kg) was
shown the satisfactory locomotion effect. At the doses of
100 and 200 mg/kg was significantly augmented the
good rearing effect of this test (Fig. 4). Extracts of B.
monniera (100 and 200 mg/kg) was shown good effect
of defecation phase (Fig. 5). Moreover, Post hoc analysis
also verified that the extract significantly increased the
locomotion, rearing and defecation effects in comparison
to the control group (p < 0.001).
Discussion
The purpose of this study was assessed the antidepressant-
like effect of MEBM using animal behavioral models. A
major problem in the screening for new antidepres-
sant effect is the establishment of a valid animal
model able to sufficiently and accurately identified di-
verse depressant treatments, without making errors of
omission [35]. In that case, the forced swimming and
tail suspension tests are widely accepted behavioral
models for the assessment of antidepressant activity.
The characteristic behavior evaluated in these tests,
termed immobility, has been considered to reflect be-
havioral despair similar to that seen in human de-
pression, and it is well known that antidepressant
drugs are able to reduce the immobility time in ro-
dents [30]. It is interesting to note that the immobil-
ity shown by mice when subjected to unavoidable
stress such as forced swimming test is thought to reflect a
state of despair or lowered mood, which is thought to re-
flect depressive disorders in humans. In addition, the im-
mobility time is reduced by treatment with antidepressant
drugs [36]. There is a significant correlation between the
clinical efficacy of antidepressant drugs and their potency
in the FST, this was not found in any other model [34, 36].
Interestingly, our data indicate that higher doses of plant
extracts were more effective than smaller doses both in
forced swimming and tail suspension tests.
Based on our present study, antidepressant-like effect
of MEBM in all the classic models of depressants, where
it was found to possess antidepressant-like activity com-
parable to the standard drug Imipramine hydrochloride.
Imipramine hydrochloride acts by inhibiting norepin-
ephrine (NE) reuptake and has been used as a standard
drug in majority studies. The beneficial effect of Imipra-
mine hydrochloride in the forced swimming test model
seems to be due to increased availability of these neuro-
transmitters (NE) and serotonin (5HT) at the post syn-
aptic site following reuptake inhibition [37].
Initial hypothesis of depression has been formulated
about 40 years ago, proposing that the main symptoms
of depression due to functional deficiency of cerebral
monoaminergic transmitters such as (NE), 5HT, and
dopamine (DA) located at synapses [38]. Some studies
have also shown the adaptogenic effect of the plant
Fig. 3 Graphical representation of antidepressant effect of B. monniera extract on locomotor activity test of rearing in mice
Table 4 Antidepressant effects of methanolic extract of B. monniera in measurement of locomotor activity test
Treatment Doses (mg/kg) Locomotion Rearing Defecation
Deionized water 0.1 mL/mice 107.80 ± 2.92 23.00 ± 2.02 1.00 ± 0.31
Imipramine hydrochloride 30 206.60 ± 3.01* 36.60 ± 1.60* 3.20 ± 0.37*
MEBM 50 91.40 ± 4.25* 27.80 ± 2.13 1.60 ± 0.40
MEBM 100 121.40 ± 4.46 37.20 ± 1.93* 3.20 ± 0.37*
MEBM 200 153.80 ± 3.61* 47.20 ± 2.03* 4.20 ± 0.37*
Values are presented as mean ± SEM (n = 5). MEBM =Methanolic extract of B.monniera
*p < 0.001 compared with the control group (Dunnett’s test)
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extract via normalization of the various stress parame-
ters and monoaminergic levels which may provide a clue
that the extract is bringing their possible antidepressant-
like effect through restoration of normal monoaminergic
neurotransmitters [39].
Brahmi contains a natural phytonutrients which is
known as bacosides. This is responsible for improving
vital neurotransmitters activities which happen in
memorization and information process and may be help-
ful in depression [40]. The action of the triterpinoid sa-
ponins and the bacosides A and B has resulted in the
enhancement of the nerve impulse transmission. Neuro-
chemical assays suggested that treatment by bacosides
or bacopasides I improved brain antioxidant activity to
varying degrees after the behavioral despair test. These
findings indicated that the antidepressant-like effect of
bacopasides I might be related to both antioxidant acti-
vation and noradrenergic activation [41]. Three new tri-
terpene glycosides, bacopasides VI-VIII, together with
three known analogues, bacopaside I (1) , bacopaside II
(2) and bacopa saponsin C (3), were isolated from the
whole plant of B. monniera. Compounds 1, 2 and 3 were
shown antidepressant activity when tested on forced
swimming and tail suspension in mice, respectively [42].
Recently, oxidative stress was linked with the patho-
physiology of major depression, with significant correla-
tions being found between the severity of depression and
erythrocyte superoxide dismutase/lipoperoxidation levels
[43]. Meanwhile, treatment with antidepressants reduces
the oxidative stress related to depressive disorder [44, 45].
Additionally, some species such as Bacopa monneira,
Withania somnifera and Asparagus racemosus, all of
which are reported to have antidepressant-like properties,
also possess antioxidant activity [46–48]. Therefore , it is
possible that the antioxidant activity of the methanol
extract from B. monniera may contribute to its
antidepressant-like effect. However, different kinds of
the research study must needed to elucidate the
mechanism of action of B. monniera in the CNS, the
pattern of effects were observed in these experiments
suggest the involvement of the norepinephrine neuro-
transmitters system on its antidepressant-like effects.
Fig. 5 Graphical representation of antidepressant effect of B. monniera extract on tail suspension test in mice
Fig. 4 Graphical representation of antidepressant effect of B. monniera extract on locomotor activity test of defecation in mice
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Conclusions
In the present investigation, we have reported anti-
depressant-like effect of MEBM in all the classic models
such as forced swimming test (FST), measurement of loco-
motor activity test (MLAT) and tail suspension test (TST),
where it was found to possess significant antidepressant-
like activity comparable to the standard drug Imipramine
hydrochloride. Different kinds of the research study must
needed to elucidate the mechanism of action of B. mon-
niera in the CNS, the pattern of effects were observed in
these experiments suggest the involvement of norepineph-
rine neurotransmitters system on its antidepressant-like
effect. The present study also warrants further investi-
gation into identification of the active compounds in
herbal medicines, in particular extract of B. monniera
with antidepressant-like effects.
Abbreviation
MEBM: Methanolic extract of Bacopa monniera; FST: Forced swimming
test; ICDDR, B: International Center for Diarrheal Disease and Research,
Bangladesh; TST: Tail suspension test.
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